Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)

摘要: Objective To analyze damage occurring in patients with Wegener's granulomatosis (WG) enrolled the WG Etanercept Trial (WGET) and to correlate that disease activity, adverse events, quality of life. Methods The Vasculitis Damage Index (VDI) was applied all 180 at trial entry every 6 months throughout trial. Items were analyzed by presumed etiology (i.e., secondary WG, therapy, or both) time occurrence. Spearman's rank correlation coefficients calculated between VDI scores Birmingham Activity Score for (BVAS/WG), frequency flares, number patients' quality-of-life assessments. Results The mean score 1.3 study enrollment 1.8 end This increase due occurred despite (or because of) including visual impairment, hearing loss, nasal blockade, pulmonary fibrosis, hypertension, renal insufficiency, peripheral neuropathy, gonadal failure, diabetes mellitus. Only 11% had not sustained a single item after 1 year enrollment. When adjusted baseline VDI, BVAS/WG correlated moderately well (r = 0.20, P 0.015). Increases also particularly among limited (P 0.06). Conclusion Damage from both active its treatment remain important problems WG. Despite dramatic improvements patient survival achieved over last several decades, only few emerge period without sustaining some itself, treatment, both. An measure future therapeutic approaches will be their ability reduce accrued time.